Ebenau, Jarith L. http://orcid.org/0000-0001-5447-7224
Visser, Denise
Verfaillie, Sander C. J.
Timmers, Tessa
van Leeuwenstijn, Mardou S. S. A.
Kate, Mara ten
Windhorst, Albert D.
Barkhof, Frederik
Scheltens, Philip
Prins, Niels D.
Boellaard, Ronald
van der Flier, Wiesje M.
van Berckel, Bart N. M.
Article History
Received: 30 March 2022
Accepted: 24 August 2022
First Online: 8 September 2022
Declarations
:
: The study was approved by the medical ethical committee of the VU University and was in accordance with the Helsinki Declaration of 1975.
: All participants gave written informed consent.
: Jarith Ebenau reports no disclosures relevant to the manuscript.Denise Visser reports no disclosures relevant to the manuscript.Sander Verfaillie reports no disclosures relevant to the manuscript.Tessa Timmers reports no disclosures relevant to the manuscript.Mardou van Leeuwenstijn reports no disclosures relevant to the manuscript.Mara ten Kate reports no disclosures relevant to the manuscript.Frederik Barkhof is a consultant for Biogen-Idec, Bayer-Schering, Merck-Serono, Roche, NovartisIXICO, and Combinostics; has received sponsoring from European Commission-Horizon 2020, National Institute for Health Research-University College London Hospitals Biomedical Research Centre, TEVA, Novartis, and Biogen; and serves on the editorial boards of <i>Radiology</i>, <i>Brain</i>, <i>Neuroradiology</i>, <i>Multiple Sclerosis Journal</i>, and <i>Neurology.</i>Philip Scheltens has acquired grant support (for the institution) from Biogen. In the past two years, he has received consultancy/speaker fees (paid to the institution) from Probiodrug Biogen, EIP Pharma, Merck AG.Niels Prins is consultant to Boehringer Ingelheim, Aribio, and Amylyx. He is co-PI of a study with Fuji Film Toyama Chemical. He serves on the DSMB of Abbvie’s M15-566 trial. NP has received a speaker fee from Biogen. Payments were made to his company. He is CEO and co-owner of the Brain Research Centre, The Netherlands.Ronald Boellaard reports no disclosures relevant to the manuscript.Bert Windhorst reports no disclosures relevant to the manuscript.Wiesje van der Flier Research programs have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF is recipient of a grant for the Heart-Brain Connection crossroads (HBCx) consortium of the Dutch CardioVascular Alliance (DCVA). This work was supported by the Dutch Heart Foundation [#2018–28]. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai and WebMD Neurology (Medscape). WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF was associate editor at <i>Alzheimer’s Research & Therapy</i> (2020–2021); She is associate editor of <i>Brain</i> (2021–). All funding is paid to her institution.Bart van Berckel has received research support from EU-FP7, CTMM, ZonMw, NWO, and Alzheimer Nederland. BvB has performed contract research for Rodin, IONIS, AVID, Eli Lilly, UCB, DIAN-TUI, and Janssen. BvB was a speaker at a symposium organized by Springer Healthcare. BvB has a consultancy agreement with IXICO for the reading of PET scans. BvB is a trainer for GE. BvB only receives financial compensation from Amsterdam UMC.